Book your seat

Online Live Training Features

All sessions of this unique course online

Live interaction options between the delegates and trainer

Available via mobile, tablet or laptop

Meet the training leaders

  • Susanne Michel MD, MSc
  • Co-founder
  • Ascenian Consulting, Germany
Learn more about the trainer
  • Noemi Muszbek MSc
  • Health Economics Director, Partner
  • Visible Analytics, United Kingdom
Learn more about the trainer
  • Edit Remak MSc, PhD
  • Health Economics Director, Partner
  • Visible Analytics, Hungary
Learn more about the trainer

Course description

This unique course provides a practical & in-depth understanding of HTA decision making across EU markets and will focus on the evidence generation underpinning a convincing value proposition to different HTAs. It will provide the tools to understand and critically appraise the evidence and studies required for HTA submissions, and to be able to put together an evidence plan including the underpinning data requirements and understanding the role of patients, cost-effectiveness models, access schemes and scientific advice.

The two-day training is structured in a way that participants can connect the strategic importance of process requirements to underlying of methods and optimal evidence. The training offers practical insights of former payer decision makers, method specialists and direct experience from HTA dossier submission and defense in different HTA driven markets. While HTA methods and processes are likely to change in the 2020’s significantly and rapidly, this course will allow understanding current practices, learning about future plans, and discussing potential changes in both process and requirements. During the course there will be opportunities to discuss indication -, market and molecule specifics, allowing for learning close to the participants challenges. The course will be interactive, participative and collaborative and build on the business aspirations of pharmaceutical and biotech companies and direct problem solving.

Join us & understand the strategies for patient access in an evolving value-based and patient-centric healthcare.

Key topics

The role of patients in HTA decision-making

Optimizing the generation and the use of evidence in HTA

From Quality of Life to QALYs

Cost-effectiveness model & budget impact

HTA for cell & gene therapies

Access schemes & contracting

Scientific advice

Shaping the EU HTA trend

Benefits of attending

Gain examples of HTA processes across England, France, Germany, Italy and Spain

Understand what constitutes a valid Value Proposition from an HTA perspective

Learn about the difference in value propositions for HTAs and pricing agencies

Gain insight into the type of evidence required for HTAs around the world

Understand the role of patients in HTA decision making

Explore early modeling for identifying potential value messages and data gaps

Differences across markets on evidence expectations

Understand and be able to prepare for methodological and data expectations including economic evaluations, use of RWE and post launch requirements

The be able to understand and critically appraise costeffectiveness evidence for HTA submission purposes

Understand HTA challenges & payer approaches for cell & gene therapies

Reveal evidence considered for access schemes

Discover future EU HTA trends and how to get ready for the future


Online Live Stream

from 1196 € Buy


Based on your specific needs and goals, we will build a training program that will equip your employees with the right set of skills and practical knowledge to achieve your organization's targets.

Request in-house training

Sneak peek into the program

Get the complete program line-up, speaker details and more.

Download brochure

Fill in details below to download your PDF brochure.

Contact us